PPARγ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis

Jee Young Han, Ye Ji Kim, Lucia Kim, Suk Jin Choi, In Suh Park, Joon Mee Kim, Young Chae Chu, Dae-Ryong Cha

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The peroxisome proliferator activated receptor (PPAR)γ agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPARγ agonist and interaction with angiotensin receptor antagonist in the unilateral ureteral obstruction (UUO) model. After UUO, mice were divided to four groups: no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+ pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and pSmad2 demonstrated that their expressions were increased in CONT group and decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group. The expression of TGF-β1 from real time RT PCR showed markedly increased in the CONT group and decreased in all treated groups compared to CONT. These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the synergism between pioglitazone and L158809 is not clear. Considering decreased expression of PAI-1 and TGF-β/Smad2 in the treated groups, PAI-1 and TGF-β are likely linked to the decreased renal tubulointerstitial fibrosis. According to these results, the PPARγ agonist might be used in the treatment of renal fibrotic disease.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalJournal of Korean Medical Science
Volume25
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

pioglitazone
Peroxisome Proliferator-Activated Receptors
Angiotensin Receptor Antagonists
Plasminogen Activator Inhibitor 1
Fibrosis
Kidney
Ureteral Obstruction
Hypoglycemic Agents
Real-Time Polymerase Chain Reaction
Western Blotting

Keywords

  • Angiotensin
  • Fibrosis
  • Plasminogen activator inhibitor 1
  • PPAR gamma
  • Receptors
  • Transforming growth factor beta

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PPARγ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. / Han, Jee Young; Kim, Ye Ji; Kim, Lucia; Choi, Suk Jin; Park, In Suh; Kim, Joon Mee; Chu, Young Chae; Cha, Dae-Ryong.

In: Journal of Korean Medical Science, Vol. 25, No. 1, 01.01.2010, p. 35-41.

Research output: Contribution to journalArticle

Han, Jee Young ; Kim, Ye Ji ; Kim, Lucia ; Choi, Suk Jin ; Park, In Suh ; Kim, Joon Mee ; Chu, Young Chae ; Cha, Dae-Ryong. / PPARγ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. In: Journal of Korean Medical Science. 2010 ; Vol. 25, No. 1. pp. 35-41.
@article{97e75a84bd1b43ffa22da986004c624e,
title = "PPARγ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis",
abstract = "The peroxisome proliferator activated receptor (PPAR)γ agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPARγ agonist and interaction with angiotensin receptor antagonist in the unilateral ureteral obstruction (UUO) model. After UUO, mice were divided to four groups: no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+ pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and pSmad2 demonstrated that their expressions were increased in CONT group and decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group. The expression of TGF-β1 from real time RT PCR showed markedly increased in the CONT group and decreased in all treated groups compared to CONT. These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the synergism between pioglitazone and L158809 is not clear. Considering decreased expression of PAI-1 and TGF-β/Smad2 in the treated groups, PAI-1 and TGF-β are likely linked to the decreased renal tubulointerstitial fibrosis. According to these results, the PPARγ agonist might be used in the treatment of renal fibrotic disease.",
keywords = "Angiotensin, Fibrosis, Plasminogen activator inhibitor 1, PPAR gamma, Receptors, Transforming growth factor beta",
author = "Han, {Jee Young} and Kim, {Ye Ji} and Lucia Kim and Choi, {Suk Jin} and Park, {In Suh} and Kim, {Joon Mee} and Chu, {Young Chae} and Dae-Ryong Cha",
year = "2010",
month = "1",
day = "1",
doi = "10.3346/jkms.2010.25.1.35",
language = "English",
volume = "25",
pages = "35--41",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "1",

}

TY - JOUR

T1 - PPARγ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis

AU - Han, Jee Young

AU - Kim, Ye Ji

AU - Kim, Lucia

AU - Choi, Suk Jin

AU - Park, In Suh

AU - Kim, Joon Mee

AU - Chu, Young Chae

AU - Cha, Dae-Ryong

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The peroxisome proliferator activated receptor (PPAR)γ agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPARγ agonist and interaction with angiotensin receptor antagonist in the unilateral ureteral obstruction (UUO) model. After UUO, mice were divided to four groups: no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+ pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and pSmad2 demonstrated that their expressions were increased in CONT group and decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group. The expression of TGF-β1 from real time RT PCR showed markedly increased in the CONT group and decreased in all treated groups compared to CONT. These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the synergism between pioglitazone and L158809 is not clear. Considering decreased expression of PAI-1 and TGF-β/Smad2 in the treated groups, PAI-1 and TGF-β are likely linked to the decreased renal tubulointerstitial fibrosis. According to these results, the PPARγ agonist might be used in the treatment of renal fibrotic disease.

AB - The peroxisome proliferator activated receptor (PPAR)γ agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPARγ agonist and interaction with angiotensin receptor antagonist in the unilateral ureteral obstruction (UUO) model. After UUO, mice were divided to four groups: no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+ pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and pSmad2 demonstrated that their expressions were increased in CONT group and decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group. The expression of TGF-β1 from real time RT PCR showed markedly increased in the CONT group and decreased in all treated groups compared to CONT. These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the synergism between pioglitazone and L158809 is not clear. Considering decreased expression of PAI-1 and TGF-β/Smad2 in the treated groups, PAI-1 and TGF-β are likely linked to the decreased renal tubulointerstitial fibrosis. According to these results, the PPARγ agonist might be used in the treatment of renal fibrotic disease.

KW - Angiotensin

KW - Fibrosis

KW - Plasminogen activator inhibitor 1

KW - PPAR gamma

KW - Receptors

KW - Transforming growth factor beta

UR - http://www.scopus.com/inward/record.url?scp=77949324227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949324227&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.1.35

DO - 10.3346/jkms.2010.25.1.35

M3 - Article

VL - 25

SP - 35

EP - 41

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 1

ER -